Dupilumab
FDA approved dupilumab for treatment of chronic spontaneous urticaria
The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment, according to a company press release.
Dupilumab, tezepelumab lead biologic initiations for severe asthma
SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.
Risk factors impact denials, wait times, discontinuations in biologic treatment for asthma
SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.
Itch, urticaria activity improve with dupilumab after refractory antihistamine treatment
SAN DIEGO — Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.
Dupilumab improves lichenification in atopic dermatitis across age, racial groups
Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive scratching, among patients of varying ages and races with atopic dermatitis, according to a study.
Adherence to asthma biologics varies by therapy given, tends to be low
SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.
Eosinophilic esophagitis improves with dupilumab regardless of food elimination diets
SAN DIEGO — Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food elimination diets during treatment, according to a poster presented here.
Baseline factors impact odds for clinical remission with dupilumab in asthma
SAN DIEGO — Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric oxide levels in a moderate to severe asthma cohort, according to a poster presented here.
Dupilumab linked to reduced risks for psychiatric disorders in atopic dermatitis
Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals of Allergy, Asthma & Immunology.
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.